Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

DISEASE CHARACTERISTICS:

• Diagnosis of primary malignant glioblastoma multiforme (i.e., grade IV anaplastic astrocytoma)
• Primary treatment (surgery, radiation, and/or chemotherapy) has been completed
• Candidate for surgery and willing to undergo craniotomy
• No progressive or recurrent disease
• No residual disease that requires reoperation, additional gamma therapy, or other modality

PATIENT CHARACTERISTICS:

• ECOG performance status (PS) 0-2 OR Karnofsky PS 70-100% (i.e., if symptomatic, bedridden \< half of a waking day)
• Life expectancy ≥ 2 months
• Not pregnant
• Negative pregnancy test
• U.S. residents only
• No hematopoietic, hepatic, renal, cardiovascular, or pulmonary laboratory values or other medical circumstances that would preclude surgery or aldesleukin therapy
• No serious concurrent medical or psychiatric illness that would preclude informed consent or study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• At least 4 weeks since prior anticancer therapy and recovered
• Prior stereotactic or gamma knife radiosurgery allowed